Another study has reported that cancer cells may activate CAFs in a paracrine manner, and as a result, several secretory factors such as CCL2, are upregulated, resulting in chemotherapeutic resistance in breast cancers [23]. This evidence concerns the gene CCL2 and breast carcinoma.